My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 99

    1.

    Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.

    Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, Butler AE, Butler PC.

    Diabetes. 2009 Jul;58(7):1604-15. Epub 2009 Apr 29.PMID: 19403868 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.

    Diabetes Care. 2006 Dec;29(12):2638-43.PMID: 17130197 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.

    Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP.

    Diabetes Obes Metab. 2008 Dec;10(12):1212-20. Epub 2008 May 12.PMID: 18476982 [PubMed - indexed for MEDLINE]Related articles

    4.

    New combination treatments in the management of diabetes: focus on sitagliptin-metformin.

    Green J, Feinglos M.

    Vasc Health Risk Manag. 2008;4(4):743-51. Review.PMID: 19065992 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes.

    Matveyenko AV, Butler PC.

    Diabetes. 2006 Jul;55(7):2106-14.PMID: 16804082 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.

    Gallwitz B.

    Drugs Today (Barc). 2007 Oct;43(10):681-9.PMID: 17987221 [PubMed - indexed for MEDLINE]Related articles

    7.

    Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes.

    Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC.

    Diabetes. 2004 Jun;53(6):1509-16.PMID: 15161755 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Sitagliptin: a novel drug for the treatment of type 2 diabetes.

    Choy M, Lam S.

    Cardiol Rev. 2007 Sep-Oct;15(5):264-71. Review.PMID: 17700385 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

    Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group.

    Diabetes Care. 2007 Aug;30(8):1979-87. Epub 2007 May 7. Erratum in: Diabetes Care. 2008 Aug;31(8):1713. PMID: 17485570 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.

    Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M.

    Curr Med Res Opin. 2008 Feb;24(2):537-50.PMID: 18194595 [PubMed - indexed for MEDLINE]Related articles

    11.

    Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.

    Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP.

    Curr Med Res Opin. 2008 Feb;24(2):489-96. Review.PMID: 18182122 [PubMed - indexed for MEDLINE]Related articles

    12.

    New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.

    Gagliardino JJ, Santoro S, Arellano S, Di Girolamo G.

    Expert Opin Pharmacother. 2008 Jun;9(9):1495-507. Review.PMID: 18518780 [PubMed - indexed for MEDLINE]Related articles

    13.

    Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

    Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB.

    Diabetes. 2006 Jun;55(6):1695-704.PMID: 16731832 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks.

    [No authors listed]

    Prescrire Int. 2008 Feb;17(93):12-5.PMID: 18354861 [PubMed - indexed for MEDLINE]Related articles

    15.

    Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.

    Pham DQ, Nogid A, Plakogiannis R.

    Am J Health Syst Pharm. 2008 Mar 15;65(6):521-31. Review.PMID: 18319497 [PubMed - indexed for MEDLINE]Related articles

    16.

    Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

    Zerilli T, Pyon EY.

    Clin Ther. 2007 Dec;29(12):2614-34. Review.PMID: 18201579 [PubMed - indexed for MEDLINE]Related articles

    17.

    Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide.

    Hull RL, Shen ZP, Watts MR, Kodama K, Carr DB, Utzschneider KM, Zraika S, Wang F, Kahn SE.

    Diabetes. 2005 Jul;54(7):2235-44.PMID: 15983227 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group.

    Clin Ther. 2006 Oct;28(10):1556-68.PMID: 17157112 [PubMed - indexed for MEDLINE]Related articles

    19.

    Managed care perspective on three new agents for type 2 diabetes.

    VanDeKoppel S, Choe HM, Sweet BV.

    J Manag Care Pharm. 2008 May;14(4):363-80. Review.PMID: 18500914 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Longitudinal ultrastructure study of islet amyloid in the HIP rat model of type 2 diabetes mellitus.

    Hayden MR, Karuparthi PR, Manrique CM, Lastra G, Habibi J, Sowers JR.

    Exp Biol Med (Maywood). 2007 Jun;232(6):772-9.PMID: 17526769 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity